Core Insights - China Resources Pharmaceutical (华润医药) reported a total revenue of 8.283 billion RMB for the nine months ending September 30, 2025, representing a year-on-year decline of 3.1% [1] - The net profit for the same period was 1.388 billion RMB, which is a decrease of 1.7% compared to the previous year [1] Financial Performance - Total revenue: 8.283 billion RMB, down 3.1% year-on-year [1] - Net profit: 1.388 billion RMB, down 1.7% year-on-year [1]

Core Viewpoint - China Resources Pharmaceutical (03320.HK) reported a total revenue of RMB 4.766 billion for Dong'e Ejiao for the nine months ending September 30, 2025, representing a year-on-year growth of 4.41% [1] - The net profit for the same period was RMB 1.277 billion, reflecting a year-on-year increase of 10.77% [1] - As of the announcement date, the company directly holds 10.19% of Dong'e Ejiao's shares and approximately 23.50% through its non-wholly owned subsidiary, indicating a total effective control of about 23.50% [1] Financial Performance - Total revenue for Dong'e Ejiao reached RMB 4.766 billion, up 4.41% year-on-year [1] - Net profit amounted to RMB 1.277 billion, showing a growth of 10.77% compared to the previous year [1] - The cash and cash equivalents at the end of the period were RMB 3.238 billion [1] Ownership Structure - The company directly holds 10.19% of Dong'e Ejiao [1] - Through its subsidiary, China Resources Dong'e Ejiao Co., Ltd., the company holds approximately 23.50% [1] - The total effective control of Dong'e Ejiao by the group is approximately 23.50%, classified as a subsidiary [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 （於香港註冊成立的有限公司） （股份代號：3320） 公 告 天士力醫藥 截至2025年9月30日止九個月的未經審核財務業績 | | 2025年 | 2024年 | | --- | --- | --- | | | （人民幣） | （人民幣） | | | （未經審核） | （未經審核） | | 營業總收入 | 6,310,672,857.39 | 6,462,559,794.57 | | 淨利潤 | 992,545,465.74 | 828,144,304.95 | | 現金及現金等價物淨增加╱（減少）額 | 365,734,781.57 | (1,176,765,701.54) | | 期末現金及現金等價物餘額 | 1,183,018,844.93 | 1,020,566,903.89 | 截至 截至 | 2025年9月30日 | 2024年12月31日 | | --- | --- | | （人民幣） ...

Core Viewpoint - China Resources Pharmaceutical (03320) reported a revenue of 4.766 billion RMB for the nine months ending September 30, 2025, reflecting a year-on-year increase of 4.41% and a net profit of 1.277 billion RMB, which represents a year-on-year increase of 10.77% [1] Financial Performance - Total revenue reached 4.766 billion RMB, marking a 4.41% increase compared to the previous year [1] - Net profit amounted to 1.277 billion RMB, showing a growth of 10.77% year-on-year [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 （於香港註冊成立的有限公司） （股份代號：3320） 公 告 華潤雙鶴 截至2025年9月30日止九個月的未經審核財務業績 於2025年10月24日，華潤雙鶴公佈其截至2025年9月30日止九個月的季度報 告。 | | 2025年 | 2024年 | | --- | --- | --- | | | （人民幣） | （人民幣） | | | （未經審核） | （未經審核） | | 營業總收入 | 8,283,222,411.30 | 8,548,241,751.78 | | 淨利潤 | 1,388,212,831.84 | 1,411,764,462.20 | | 現金及現金等價物淨減少額 | （630,388,437.05） | (509,288,867.81) | | 期末現金及現金等價物餘額 | 2,207,726,715.86 | 2,698,854,450.15 | | | 截至2025年 | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 於2025年10月24日，東阿阿膠公佈其截至2025年9月30日止九個月的季度報 告。 東阿阿膠股份有限公司（「東阿阿膠」）為一家於中華人民共和國註冊成立的 公司。東阿阿膠的股份於深圳證券交易所上市。截至本公告日期，東阿阿膠 由華潤醫藥集團有限公司（「本公司」，連同其附屬公司合稱為「本集團」）直接 持有10.19%股權，通過本公司非全資附屬公司華潤東阿阿膠有限公司持有約 23.50%，本集團實際控制東阿阿膠約23.50%並入賬為本公司的附屬公司。 （於香港註冊成立的有限公司） （股份代號：3320） 公告 東阿阿膠 截至2025年9月30日止九個月的未經審核財務業績 東阿阿膠未經審核財務資料乃根據中國公認會計準則編製，且未經本公司核 數師審閱或審核，在審核過程中可能須予調整。有關財務資料僅限於東阿阿 膠，並不能全面反映本集團的營運或財務狀況。股東及潛在投資者買賣本公 司證券時務請僅慎行事，且不應完全依 ...

新京报贝壳财经讯 华润医药10月21日公告，本金总额为人民币11亿元的第一期2025年公司债券已成功 发行，期限为三年，票面年利率为1.82%。此次债券发行所募集的净额将用于生产性支出，包括偿还公 司债务、补充营运资金、项目开发与营运支出、与科技创新相关的投资及其他合法用途。 ...

格隆汇10月21日丨华润医药(03320.HK)公告，董事会欣然宣布，本金总额人民币11亿元的第一期2025年 公司债券已发行，期限三年，票面年利率为1.82%。发行第一期2025年公司债券所募集的所得款项净额 将用于生产性支出，包括偿还公司债务、补充营运资金、项目开发与营运支出、与科技创新相关的投资 以及符合适用法律法规的其他用途。 ...

Core Viewpoint - China Resources Pharmaceutical (03320) has issued the first phase of its 2025 corporate bonds totaling RMB 1.1 billion, with a three-year term and an annual coupon rate of 1.82% [1] Summary by Relevant Categories Financial Details - The total principal amount of the issued bonds is RMB 1.1 billion [1] - The bonds have a maturity period of three years [1] - The coupon rate for the bonds is set at 1.82% per annum [1] Use of Proceeds - The net proceeds from the bond issuance will be utilized for productive expenditures [1] - Specific uses include debt repayment, working capital supplementation, project development and operational expenses, investments related to technological innovation, and other purposes compliant with applicable laws and regulations [1]

Core Viewpoint - China Resources Pharmaceutical (03320) has issued the first phase of its 2025 corporate bonds totaling RMB 1.1 billion, with a three-year term and an annual coupon rate of 1.82% [1] Summary by Categories Financial Details - The total principal amount of the issued bonds is RMB 1.1 billion [1] - The bonds have a maturity period of three years [1] - The coupon rate for the bonds is set at 1.82% per annum [1] Use of Proceeds - The net proceeds from the bond issuance will be utilized for productive expenditures [1] - Specific uses include debt repayment, working capital supplementation, project development and operational expenses, investments related to technological innovation, and other purposes compliant with applicable laws and regulations [1]